A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck

NCT ID: NCT02054442

Last Updated: 2021-03-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-08-31
• Study Completion Date: 2022-12-31

Brief Summary

The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial for the patient. Because no data on this combination are available the investigators will start with a phase Ib study to investigate the feasibility of the schedule.

Detailed Description

The addition of cetuximab to cisplatin and 5-FU in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) showed an improvement of overall survival (OS), progression free survival (PFS) and response rate (RR). However, cisplatin and 5-FU are toxic cytostatics for the vulnerable recurrent or metastatic SCCHN patient. As one of the primary goals in these patients is palliation, in some patients treatment with cisplatin, 5-FU and cetuximab is not feasible owing to a low performance score (PS of 2) or the patient refusal to receive chemotherapy, i.e. cisplatin and 5-FU, possibly influencing quality of life negatively.

Methotrexate is a cytostatic which has shown to have modest activity in recurrent or metastatic SCCHN. The RR is between 14 and 20%, the median PFS is 3 months, and there is no improvement in OS, which is only 6 months. Toxicity of MTX is very low. Patients with a PS of 2 can be treated with MTX. Patients refusing treatment with cisplatin, 5-FU and cetuximab, frequently choose MTX as palliative treatment.

No data are available on the combination of cetuximab and MTX. The investigators will perform a randomized phase II study to investigate if the addition of cetuximab to MTX is beneficial, i.e. an improvement in the PFS, for the patient. Because no data on this combination are available the investigators will start with a phase Ib study to investigate the feasibility of the schedule.

Conditions

Squamous Cell Carcinoma of the Head and Neck

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: MTX in combination with cetuximab

The dosage of cetuximab will be i.v. 400 mg/m2 over a period of 2h for the first infusion, followed by infusions of 250 mg/m2 over 1 hour once weekly. Cetuximab will be dissolved in 500 ml NaCl 0.9%.

Premedication: H1-receptor antagonist and dexamethasone.

The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.

Premedication: ondansetron 8 mg.

Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient.

Group Type: EXPERIMENTAL

Cetuximab

Intervention Type: DRUG

We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.

Methotrexate

Intervention Type: DRUG

Arm B: MTX

The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.

Premedication: ondansetron 8 mg.

Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient.

Group Type: ACTIVE_COMPARATOR

Methotrexate

Intervention Type: DRUG

Interventions

Cetuximab

We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.

Intervention Type: DRUG

Methotrexate

Intervention Type: DRUG

Other Intervention Names

Erbitux; L01XC06; EMTHEXATE; L01BA01

Eligibility Criteria

Inclusion Criteria

• Cytologically/histologically-proven SCCHN
• Recurrent or metastatic SCCHN
• At least one measurable lesion as determined by RECIST v1.1 is required. Lesions in previously irradiated areas should not be considered measurable unless there is clear evidence of progression in such lesions since the radiotherapy.
• No prior systemic treatment for recurrent or metastatic disease
• Primary site: (1) oral cavity, (2) oropharynx, (3) hypopharynx, (4) larynx, or (5) unknown primary squamous cell carcinoma in the head and neck region presenting originally with lymph node metastases (N1-N3).
• Time between prior treatment and inclusion in the study (> 3 months). Palliative RT in case of painful bone metastases is allowed in phase II and after 4 weeks in phase Ib
• Ineligible (due to medical co-morbidities) or intolerant to platinum-based therapy per medical history or refusing cisplatin-based chemotherapy by the patient
• WHO performance status 0-2.
• Age >18 years
• Adequate organ function and laboratory parameters as defined by:

• Absolute neutrophil count (ANC) ≥ 1.5 x 109 /L
• Hemoglobin (Hb) ≥ 9 g/dl 5.6 mmol/l (which may be achieved by transfusion)
• Platelets (PLT) ≥ 100 x 109/L
• AST and ALT ≤ 2.5 x ULN (upper limit of normal)
• Serum bilirubin ≤ 1.5 x ULN
• Calculated creatinine clearance or MDRD > 60ml/min
• Recovered from all adverse events (AEs) of previous anti-cancer therapies. AEs related to prior radiotherapy are allowed.
• Written informed consent

Exclusion Criteria

• Serious active infections
• Patients (M/F) with reproductive potential not implementing adequate contraceptives measures
• Prior treatment with EGFR inhibitors or MTX
• Concomitant (or within 4 weeks before randomization) administration of any other experimental drug under investigation
• Concurrent treatment with any other anti-cancer therapy.
• Central nervous system involvement
• Lung fibrosis
• Pleural effusion or ascites or other third space effusions
• History of another malignancy within 2 years prior to starting study treatment, except cured basal cell carcinoma of the skin, excised carcinoma in situ of the cervix, or other head and neck cancer.
• Pregnancy or lactation
• Any other condition that would, in the Investigator's judgment, preclude patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g. infection/inflammation, intestinal obstruction, social/psychological complications.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Serono International SA

INDUSTRY

Sponsor Role: collaborator

Leiden University Medical Center

OTHER

Sponsor Role: collaborator

Academisch Ziekenhuis Maastricht

OTHER

Sponsor Role: collaborator

Erasmus Medical Center

OTHER

Sponsor Role: collaborator

Medisch Spectrum Twente

OTHER

Sponsor Role: collaborator

Medical Center Haaglanden

OTHER

Sponsor Role: collaborator

Elisabeth-TweeSteden Ziekenhuis

OTHER

Sponsor Role: collaborator

Frisius Medisch Centrum

OTHER

Sponsor Role: collaborator

Radboud University Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Carla M van Herpen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Radboud University Medical Center

Locations

Medisch Spectrum Twente

Enschede, , Netherlands

Medical Centre Leeuwarden

Leeuwarden, , Netherlands

Leiden University Medical Center

Leiden, , Netherlands

Academisch Ziekenhuis Maastricht

Maastricht, , Netherlands

Radboud university medical center

Nijmegen, , Netherlands

Erasmus Medical Center

Rotterdam, , Netherlands

Medical Centre Haaglanden

The Hague, , Netherlands

St. Elisabeth Ziekenhuis

Tilburg, , Netherlands

Countries

Netherlands

Other Identifiers

2013-002886-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

DHNS 2013-01

Identifier Type: OTHER

Identifier Source: secondary_id

MOHN01

Identifier Type: -

Identifier Source: org_study_id